Sign inJoin waitlistJoin the waitlist

Marijo Bilusic

Clinical Research Lead · University of Miami/Jackson Health System

Credentials: · · · · · · · ·

History

University of Miami/Jackson Health System
Present

U.S. Department of Health and Human Services
2007–2010
National Cancer Institute
2005–2007
Seton Hall University
2002–2005
MED FAK SVEUCILISTA U ZAGREBU, ZAGREB
1998–2002

Research

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
European Urology · 2015 · 414 citations
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer · 2019 · First of 12 authors · 238 citations
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Journal for ImmunoTherapy of Cancer · 2018 · 233 citations

James Gulley
38 papers
Ravi Madan
33 papers
Fatima Karzai
23 papers
WD
William Dahut
15 papers
Elizabeth Plimack
11 papers
Julius Strauss
11 papers
CH
Christopher Heery
9 papers · 2 as a fellow
Jason Redman
8 papers · 2 as a fellow
Daniel Geynisman
7 papers
Margaret Gatti-Mays
7 papers · 1 as a fellow
William Figg
7 papers
YW
Yu-Ning Wong
7 papers

Grants

NIH Hematology Oncology Fellowship Program
National Cancer Institute · ZIE
Contact PI · $28.6M · Division of Basic Sciences - Nci

Clinical trials

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Site PI · Recruiting · Phase 1
K36 Therapeutics, Inc.
2025–2028